#ADA2022 – RCT: Tirzepatide once weekly for the treatment of obesity.

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide – American Diabetes Association

Commentary on Twitter

SURMOUNT-1: In an RCT, adults with obesity treated with weekly tirzepatide had major weight loss over 72 weeks. #ADA2022 https://t.co/X2RrvYxzsV pic.twitter.com/X27bWp1Qod

— NEJM (@NEJM) June 4, 2022